Last reviewed · How we verify
NCT04123119
Development of a Live Attenuated Rotavirus Vaccine as a Human Infection Challenge Model
NA trial testing Rotavirus vaccine in Diarrhoeal Disease in 22 participants. Completed in 10 May 2019.
10 May 2019
Quick facts
| Lead sponsor | Centre for Infectious Disease Research in Zambia |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 22 |
| Start date | 22 January 2019 |
| Primary completion | 10 May 2019 |
| Estimated completion | 10 May 2019 |
| Sites | 1 location across Zambia |
Drugs / interventions tested
- Rotavirus vaccine — full drug profile →
Conditions studied
- Diarrhoeal Disease — all drugs for Diarrhoeal Disease →
Sponsor
Centre for Infectious Disease Research in Zambia — full company profile →
Who can join
Adults 6 Weeks to 8 Weeks, any sex, with Diarrhoeal Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The impact of licensed rotavirus vaccines in LMICs is limited by their lower immunogenicity and efficacy in these settings. Improved vaccines and vaccination schedules would result in substantially greater reductions in infant diarrhoeal disease and mortality. Placebo-controlled trials of new rotavirus vaccines are no longer ethical, leading to challenges for traditional routes of licensure for vaccines that are in the development pipeline. A HIC model of rotavirus would address these challenges, whilst also offering an opportunity to study the causes of poor oral vaccine immunogenicity. Rotarix™ is in routine use in Zambia administered at 6 and 10 weeks infant age. Shedding of rotavirus vaccine after vaccination has recently been explored as a measure of mucosal immunity, analogous to oral poliovirus vaccine challenge models. We propose to explore methodological development of an attenuated vaccine as a HIC model to advance rotavirus immunology and vaccinology in Zambian infants. We will evaluate use of minimally invasive procedures including sublingual/submandibular sampling and stool collection for viral shedding as measures of vaccine-induced and naturally acquired mucosal immunity. This approach holds the potential to develop the first rotavirus HIC model in a low-income country and could be used to accelerate licensure of new rotavirus vaccines and explore causes of poor oral vaccine efficacy as well as correlates of vaccine protection. To do this, we will recruit a cohort of 22 Zambian infants receiving Rotarix™ at 6 and 10 weeks as part of their routine immunisation. Infants will be followed up actively on the day of vaccination, days 1,3,5 and 7 following each vaccine dose for collection of stool and saliva samples. Blood samples for IgA and IgG titres will be collected on days 0, 28, 31 and 56, and standard ELISA methods used to determine vaccine seroconversion. The work brings together collaborators at the Centre for Infectious Disease Research in Zambia, Imperial College in UK and Christian Medical College, Vellore in India to prepare the Zambian centre as a potential HIC model site.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04123119
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rotavirus vaccine
Trials testing the same drug.
- NCT06647407 — Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in · Phase 1, PHASE2 · active not recruiting
- NCT06397768 — Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddler · Phase 3 · terminated
- NCT05794230 — Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccine · Phase 3 · completed
- NCT01480258 — Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) · Phase 3 · completed
Other Centre for Infectious Disease Research in Zambia trials
Trials by the same sponsor.
- NCT07107516 — Phase 1b Ascending Dose Study of PanChol in Healthy Volunteers · Phase 1 · not yet recruiting
- NCT06903143 — Piloting a Biomarker-augmented Alcohol Screening, Brief Intervention, and Referral to Treatment (SBIRT) Program Among HI · NA · not yet recruiting
- NCT06503666 — Zambian Informed Motivated Aware Responsible Adolescent Girls and Adults · NA · recruiting
- NCT07021092 — PERSON-CENTERED APPROACHES TO VIREMIA: CONNECTION, RAPPORT, AND ENGAGEMENT STUDY · NA · recruiting
- NCT06904521 — OH Baseline Research Study · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04123119 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre for Infectious Disease Research in Zambia
- Last refreshed: 14 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04123119.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing